Liquid Biopsy clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
open to eligible people ages 18-80
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
Los Angeles, California and other locations
Our lead scientists for Liquid Biopsy research studies include Richard Everson, MD.
Last updated: